Roche CEO Worried About U.K. Drug Research Following BrexitBy
Schwan says patient access to medicines spurs innovation
Brexit may also be opportunity to redesign U.K. approach
The U.K.’s decision to leave the European Union poses a threat to research and development in the pharmaceutical industry, Roche Holding AG Chief Executive Officer Severin Schwan said.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.